Life Sciences

  • February 10, 2026

    Lutnick Rules Out Creating Value-Based Fees For Patents

    Commerce Secretary Howard Lutnick told a Senate panel Tuesday that the government is not planning to establish new fees for U.S. patents based on their value, saying the idea he was reportedly considering "is not going anywhere."

  • February 10, 2026

    Lipid Testing Patents Recite Laws Of Nature, Judge Says

    A Massachusetts federal judge has dismissed a company's infringement claims against a rival over patents that cover methods of testing for lysosomal storage disorders, ruling that the patents only cited patent-ineligible laws of nature.

  • February 10, 2026

    Apple Again Pushes To Escape Masimo's $634M IP Verdict

    Apple is doubling down on its bid to have U.S. District Judge James V. Selna relieve it from a jury's $634 million infringement verdict in litigation over its Apple Watch, saying Masimo Corp. relied on an improper and "shifting" definition of a dispositive term.

  • February 10, 2026

    Pa. Hospital Settles Ex-Worker's ADA Suit Over CBD Gummy

    UPMC Pinnacle Hospitals has settled a former employee's disability discrimination suit claiming he was unlawfully fired when he tested positive for cannabis because he took cannabidiol gummies used to treat his spinal condition.

  • February 10, 2026

    Judge Questions Timing Of Case Against Harvard Researcher

    A Massachusetts federal judge on Tuesday ordered the U.S. Attorney's Office to turn over materials related to its decision to prosecute a Harvard Medical School researcher and Russian national found with inert frog embryo specimens last year at Logan Airport, calling the timing of the case "a red flag."

  • February 10, 2026

    Astellas Gets $90M From Lupin In Myrbetriq Patent Deal

    Generic-drug maker Lupin Pharmaceuticals has inked a deal to pay $90 million to settle claims that it infringed patents held by rival Astellas Pharma Inc. covering name-brand bladder drug Myrbetriq.

  • February 10, 2026

    Norton Rose Hires Cooley Life Sciences Duo In DC

    Norton Rose Fulbright has hired two life sciences attorneys from Cooley LLP in Washington, D.C., who focus on biotech and pharmaceutical intellectual property matters, in a move the firm said is an investment in IP as a core practice.

  • February 10, 2026

    Whooping Cough-Focused Biotech Wraps $115M Fundraise

    Florida-based biotechnology company ILiAD Biotechnologies Inc. on Tuesday revealed that it wrapped its latest financing round after securing $115 million from investors, which will be used to advance development on a potential whooping cough vaccine.

  • February 09, 2026

    Kurin Fights $1.6M IP Verdict As Rival Seeks More Damages

    Kurin has urged a Delaware federal judge to overturn Magnolia Medical's $1.6 million patent verdict or order a new trial, while Magnolia Medical has asked the court to bar Kurin from selling allegedly infringing "Jet" blood-culture collection products and award it supplemental damages on Kurin's sales, plus ongoing royalties and interest.

  • February 09, 2026

    Defendant Mix-Up Ends Biotech FCA Suit, For Now

    A New York federal court ruled that a relator's False Claims Act suit failed to link claims of improper COVID-19 billing and other alleged schemes to defraud Medicare to the biotech company it named as a defendant, dismissing the complaint with leave to amend.

  • February 09, 2026

    Italian Biathlete Lodges Appeal Of Olympic Doping Ban

    Italian biathlete Rebecca Passler, who was booted from the Olympic team last week after a positive doping test, has appealed the decision to the Court of Arbitration for Sport, asserting that the test result arose from a contamination issue.

  • February 09, 2026

    Fed. Circ. Sends Blood Pump Patent Fight Back To Mass.

    The Federal Circuit on Monday reversed a lower court's ruling that Abiomed Inc. hasn't infringed five patents on blood pump systems and methods, while backing the part of the decision that cleared the medical device technology company of allegations it infringed a different patent.

  • February 09, 2026

    Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1

    Novo Nordisk AS followed through on Monday in Delaware federal court on a plan it announced last week to sue telehealth company Hims & Hers Health Inc. over its marketing of what Novo Nordisk calls a knockoff version of its GLP-1 medications.

  • February 09, 2026

    High Court Asked To Take Up Malpractice Case Against Akin

    A former Cornell University graduate student wants the U.S. Supreme Court to review the dismissal of his suit accusing Akin Gump Strauss Hauer & Feld LLP attorneys of manipulating patent litigation to steal his DNA sequencing intellectual property.

  • February 09, 2026

    Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy

    Pharmaceutical giant Eli Lilly & Co., advised by Paul Weiss Rifkind Wharton & Garrison LLP, on Monday announced that it has agreed to buy Goodwin Procter LLP-led biotechnology firm Orna Therapeutics Inc. in a deal where Orna shareholders could receive up to $2.4 billion in cash.

  • February 06, 2026

    Takeda Can't Ax Most Of Heartburn Drug Pay-For-Delay Suit

    Takeda Pharmaceutical Co. and TWi Pharmaceuticals must face most of a proposed antitrust class action accusing them of delaying the release of the generic version of Takeda's heartburn medication Dexilant, causing Walgreens, Kroger and other retailers to pay more for the brand-name drug, a California federal judge ruled Friday.

  • February 06, 2026

    Ga. Panel Backs Sperm Bank Win In 'Wrongful Birth' Case

    A Georgia appeals court backed a win for sperm bank Xytex Corp. in consolidated litigation alleging the company sold sperm under false pretenses about the medical, psychological and social history of the donors.

  • February 06, 2026

    HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight

    U.S. Department of Health and Human Services general counsel Mike Stuart announced Friday that his office referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation, a day after Novo Nordisk A/S threatened litigation over what it called the telehealth company's "knockoff" version of its popular weight loss drug Wegovy.

  • February 06, 2026

    NJ Judge Tosses Pacira Investor Suit Over Patent Loss

    A New Jersey federal judge on Friday threw out an investor lawsuit against Pacira BioSciences Inc. after a court invalidated a patent for its key pain management drug, ruling that the pharmaceutical company was not required to disclose litigation setbacks it encountered before the final ruling.

  • February 06, 2026

    Arizona Abortion Restrictions Found Unconstitutional

    An Arizona state court permanently struck down a slew of restrictions on abortion care in the state, including an ultrasound mandate and a ban on the mailing of abortion pills, finding that the restrictions violate the right to abortion enshrined in the state's constitution.

  • February 06, 2026

    PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test

    The Patent Trial and Appeal Board has found that Geneoscopy had shown that all the claims it challenged in a patent on Exact Sciences' colon cancer test Cologuard are invalid as obvious, months after the PTAB invalidated claims in a similar patent.

  • February 06, 2026

    3rd Circ. Remands J&J Unit's Libel Suit Over Talc Study

    Johnson & Johnson's talc liability unit will get another chance to pursue libel claims against a scientist over an article she wrote linking talcum power to mesothelioma, after the Third Circuit agreed to send the case back to New Jersey federal court. 

  • February 06, 2026

    TPG Hid Exactech Defects To Dodge Liability, Trust Alleges

    The settlement trust of joint implant maker Exactech filed a billion-dollar lawsuit in Delaware Chancery Court against TPG Inc., accusing the private equity firm of controlling Exactech after buying it in 2018, concealing the implants' defects, delaying product recalls and pushing the company into Chapter 11 to avoid liability.

  • February 06, 2026

    SEC Alleges Pharma Co. Misled Investors About Cancer Drug

    The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status of its cancer treatment drug.

  • February 06, 2026

    Beasley Allen Disqualified From NJ Talc Multicounty Litigation

    A New Jersey state appeals court disqualified the Beasley Allen Law Firm from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, ruling Friday that a former Faegre Drinker Biddle & Reath LLP lawyer's collaborative efforts with the firm's attorneys violated ethics rules.

Expert Analysis

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • Opinion

    Punitive Damages Awards Should Be Limited To 1st Instance

    Author Photo

    Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.

  • How Calif. High Court Is Rethinking Forum Selection Clauses

    Author Photo

    Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.

  • AI Litigation Tools Can Enhance Case Assessment, Strategy

    Author Photo

    Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

  • Lessons From Fed. Circ. On Expert Testimony In Patent Cases

    Author Photo

    Several recent decisions from the Federal Circuit are notable for their treatment of expert testimony, with relevance to the three pillars of every patent case — infringement, invalidity and damages — and offer lessons on ensuring that expert testimony is both admissible and sufficient to support the jury's verdict, say attorneys at Honigman.

  • When Atty Ethics Violations Give Rise To Causes Of Action

    Author Photo

    Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.

  • What's New In FDA's Latest Cell And Gene Therapy Guidance

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.

  • Trending At The PTAB: A Potential Barrier To Serial Challenges

    Author Photo

    New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.

  • What's Changing For Cos. In New Calif. Hazardous Waste Plan

    Author Photo

    While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.

  • Fed. Circ. In September: The Printed Matter Doctrine Expands

    Author Photo

    The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.

  • Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split

    Author Photo

    In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.

  • Series

    Practicing Stoicism Makes Me A Better Lawyer

    Author Photo

    Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.

  • Broader Eligibility For AI-Related Patents May Be Coming

    Author Photo

    A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.

  • Series

    The Biz Court Digest: Texas, One Year In

    Author Photo

    A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.